Welcome to our dedicated page for Fractyl Health news (Ticker: GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.
Fractyl Health, Inc. (Nasdaq: GUTS) is a metabolic therapeutics company focused on new approaches to obesity and type 2 diabetes (T2D), and its news flow centers on clinical data, regulatory progress, and financing activities that support these programs. The company’s updates frequently highlight developments in its Revita® endoscopic therapy and Rejuva® gene therapy platform, along with corporate and capital markets milestones.
News about Revita often covers results from the REMAIN weight maintenance program and the REVEAL‑1 Cohort, which evaluate Revita’s potential to maintain weight loss after GLP‑1 drug discontinuation. Fractyl Health has reported randomized data from the REMAIN‑1 Midpoint Cohort and open‑label data from REVEAL‑1, as well as progress in the REMAIN‑1 Pivotal Cohort and a Germany real‑world registry in inadequately controlled T2D. These releases provide detail on study designs, endpoints, safety observations, and anticipated timelines for additional data and a potential PMA submission.
Coverage of the Rejuva platform includes preclinical results from RJVA‑001 and RJVA‑002, the submission of a Clinical Trial Application module for RJVA‑001 in T2D, and presentations at scientific meetings. The company’s news describes how Rejuva is being developed as an AAV‑based, locally delivered gene therapy approach intended to support long‑term metabolic control.
Investors following GUTS news will also see announcements related to underwritten offerings of common stock, warrant structures and calls, cash runway guidance, board appointments, executive changes, and participation in healthcare conferences. Together, these items provide context on how Fractyl Health is advancing its investigational therapies, managing its capital position, and preparing for potential late‑stage and commercial‑stage activities in metabolic disease.
Fractyl Health (NASDAQ:GUTS) has reported compelling two-year real-world outcomes for its Revita® procedure from the Germany Real-World Registry study. The data shows a median 9.6% weight loss and 1.6% HbA1c reduction in patients with type 2 diabetes, sustained over two years after a single procedure.
The study involved 9 participants with a median baseline weight of 104 kg and HbA1c of 9.6%. After treatment, 7 out of 8 participants achieved ≥5% weight reduction, with median HbA1c improving from 9.6% to 7.0% at two years. Notably, no device or procedure-related serious adverse events were reported.
The company expects key data readouts from its pivotal REMAIN-1 study in Q3 2025, focusing on post-GLP-1 weight maintenance, with primary endpoint data anticipated in H2 2026.
Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes, has scheduled two important investor events. The company will release its Q1 2025 financial results and provide business updates on May 13, 2025, at 4:30 p.m. ET via a live webcast.
Additionally, CEO and Co-Founder Harith Rajagopalan, M.D., Ph.D., will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 5:00 p.m. PT. Both events will be accessible through the company's investor relations website, with recordings available for replay after the live presentations.